Science Abstracts
RELATED CONTENT
NEWS
- InSite to raise $22M to advance PhIII pipeline including combo product for lid margin disease
- Pfizer withdraws Macugen for DMO in Europe
- Comparative efficacy should have a "formal role in drug licensing"
- European generics firms, squeezed between innovators and payers, seek diversity
COMMENT
Other Informa Comment


